Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Bringing next-gen cannabinoid therapeutics to cancer patients
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Subscribe To Our Newsletter & Stay Updated
